|
Search
Collections
Benchmarks
Upload document
ADT-030
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 abstract
Abstract
Evaluation of a novel Pan-RAS/β-Catenin inhibitor, ADT-030, for treatment of pancreatic cancer.
Org:
ADT Pharmaceuticals, LLC.,
